This site uses cookies. By continuing to browse the site you are agreeing to our policy on the use of cookies.Continue
The Patient Information Leaflet (PIL) is the leaflet included in the pack with a medicine. It is written for patients and gives information about taking or using a medicine.
This PIL is in PDF format and so you must have a PDF reader installed on your device to read it.
Text only version for the visually impaired
Below is a text only representation of the Patient Information leaflet. The original may contain images or tables and can be viewed in PDF format using the link above. This PIL may be available from the RNIB in large print, Braille or audio CD. For further information please call the RNIB Medicine Leaflet line on 0800 198 5000. The product code(s) for this leaflet is/are: EU/1/00/163/001, EU/1/00/163/002.
Xeloda 150mg & 500 mg Film-coated Tablets
Package leaflet: Information for the user
Xeloda 150 mg film-coated tablets
Xeloda 500 mg film-coated tablets
capecitabine
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
What is in this leaflet
1. What Xeloda is and what it is used for
2. What you need to know before you take Xeloda
3. How to take Xeloda
4. Possible side effects
5. How to store Xeloda
6. Contents of the pack and other information
1. What Xeloda is and what it is used for
Xeloda belongs to the group of medicines called "cytostatic medicines", which stop the growth of cancer cells. Xeloda contains capecitabine, which itself is not a cytostatic medicine. Only after being absorbed by the body is it changed into an active anti-cancer medicine (more in tumour tissue than in normal tissue).
Xeloda is used in the treatment of colon, rectal, gastric, or breast cancers.
Furthermore, Xeloda is used to prevent new occurrence of colon cancer after complete removal of the tumour by surgery.
Xeloda may be used either alone or in combination with other medicines.
2. What you need to know before you take Xeloda
Do not take Xeloda:
Warnings and precautions
Talk to your doctor or pharmacist before taking Xeloda
DPD deficiency
DPD deficiency is a rare condition present at birth that is not usually associated with health problems unless you receive certain medicines. If you have an unrecognised DPD deficiency and take Xeloda, you are at an increased risk of acute early-onset of severe forms of the side effects listed under section 4 Possible side effects. Contact your doctor immediately if you are concerned about any of the side effects or if you notice any additional side effects not listed in the leaflet (see section 4 Possible side effects).
Children and adolescents
Xeloda is not indicated in children and adolescents. Do not give Xeloda to children and adolescents.
Other medicines and Xeloda
Before starting treatment, tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. This is extremely important, as taking more than one medicine at the same time can strengthen or weaken the effect of the medicines. You need to be particularly careful if you are taking any of the following:
Xeloda with food and drink
You should take Xeloda no later than 30 minutes after meals.
Pregnancy and breast-feeding
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. You must not take Xeloda if you are pregnant or think you might be.
You must not breast-feed if you are taking Xeloda.
Driving and using machines
Xeloda may make you feel dizzy, nauseous or tired. It is therefore possible that Xeloda could affect your ability to drive a car or operatemachines.
Xeloda contains anhydrous lactose
If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.
3. How to take Xeloda
Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.
Xeloda should only be prescribed by a doctor experienced in the use of anticancer medicines.
Your doctor will prescribe a dose and treatment regimen that is right for you. The dose of Xeloda is based on your body surface area. This is calculated from your height and weight. The usual dose for adults is 1250 mg/m2 of body surface area taken two times daily (morning and evening). Two examples are provided here: A person whose body weight is 64 kg and height is 1.64 m has a body surface area of 1.7 m2 and should take 4 tablets of 500 mg and 1 tablet of 150 mg two times daily. A person whose body weight is 80 kg and height is 1.80 m has a body surface area of 2.00 m2 and should take 5 tablets of 500 mg two times daily.
Your doctor will tell you what dose you need to take, when to take it and for how long you need to take it.
Your doctor may want you to take a combination of 150 mg and 500 mg tablets for each dose.
Xeloda tablets are usually taken for 14 days followed by a 7 day rest period (when no tablets are taken). This 21 day period is one treatment cycle.
In combination with other medicines the usual dose for adults may be less than 1250 mg/m2 of body surface area, and you may need to take the tablets over a different time period (e.g. every day, with no rest period).
If you take more Xeloda than you should
If you take more Xeloda than you should, contact your doctor as soon as possible before taking the next dose.
You might get the following side effects if you take a lot more capecitabine than you should: feeling or being sick, diarrhoea, inflammation or ulceration of the gut or mouth, pain or bleeding from the intestine or stomach, or bone marrow depression (reduction in certain kinds of blood cells). Tell your doctor immediately if you experience any of these symptoms.
If you forget to take Xeloda
Do not take the missed dose at all. Do not take a double dose to make up for a forgotten dose. Instead, continue your regular dosing schedule and check with your doctor.
If you stop taking Xeloda
There are no side effects caused by stopping treatment with capecitabine. In case you are using coumarin anticoagulants (containing e.g. phenprocoumon), stopping capecitabine might require that your doctor adjusts your anticoagulant dose.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
4. Possible side effects
Like all medicines, this medicine can cause side effects, although not everybody gets them.
STOP taking Xeloda immediately and contact your doctor if any of these symptoms occur:
If caught early, these side effects usually improve within 2 to 3 days after treatment discontinuation. If these side effects continue, however, contact your doctor immediately. Your doctor may instruct you to restart treatment at a lower dose.
Hand and foot skin-reaction can lead to loss of fingerprint, which could impact your identification by fingerprint.
In addition to the above, when Xeloda is used alone, very common side effects, which may affect more than 1 in 10 people are:
These side effects can become severe; therefore, it is important that you always contact your doctor immediately when you start to experience a side effect. Your doctor may instruct you to decrease the dose and/or temporarily discontinue treatment with Xeloda. This will help reduce the likelihood that the side effect continues or becomes severe.
Other side effects are:
Common side effects (may affect up to 1 in 10 people) include:
Uncommon side effects (may affect up to 1 in 100 people) include:
Some of these side effects are more common when capecitabine is used with other medicines for the treatment of cancer. Other side-effects seen in this setting are the following:
Common side effects (may affect up to 1 in 10 people) include:
Rare side effects (may affect up to 1 in 1,000 people) include:
Very rare side effects (may affect up to 1 in 10,000 people) include:
Reporting of side effects
If you get any side effects, talk to your doctor or pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below).
By reporting side effects you can help provide more information on the safety of this medicine.
Ireland
Malta
United Kingdom
5. How to store Xeloda
Keep this medicine out of the sight and reach of children.
Do not store above 30°C.
Do not use this medicine after the expiry date which is stated on the outer carton and blister after EXP. The expiry date refers to the last day of that month.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
6. Contents of the pack and other information
What Xeloda contains
What Xeloda looks like and contents of the pack
Xeloda 150 mg film-coated tablets
Light peach film-coated tablet of biconvex, oblong shape with the marking ‘150’ on the one side and ‘Xeloda’ on the other side.
Each pack contains 60 film-coated tablets (6 blisters of 10 tablets).
Xeloda 500 mg film-coated tablets
Peach film-coated tablet of biconvex, oblong shape with the marking ‘500’ on the one side and ‘Xeloda’ on the other side.
Each pack contains 120 film-coated tablets (12 blisters of 10 tablets).
Marketing Authorisation Holder
Manufacturer
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
This leaflet was last revised in June 2016
Other sources of information
Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu/.
uk-ie-mt-pil-xeloda-clean-160720-150-500mg-tabs